


Cite this: *RSC Adv.*, 2020, 10, 17854

Effect of new carbonyl cyanide aromatic hydrazones on biofilm inhibition against methicillin resistant *Staphylococcus aureus*†

Xueer Lu,^{ab} Ziwen Zhang,^c Yingying Xu,^c Jun Lu,^a Wenjian Tang^{id}^c and Jing Zhang^{id}^{*ab}

Carbonyl cyanide *m*-chlorophenylhydrazone (CCCP), as a protonophore, in combination with antibiotics exhibited potentiating antibacterial activity. To improve CCCP's potency and toxicity, a series of aromatic hydrazones were synthesized and their antimicrobial activity was evaluated; amongst them, compounds **2e** and **2j** with a strong *para*-electron-withdrawing substituent ($-\text{NO}_2$ and $-\text{CF}_3$) at the phenyl ring had the lowest MICs against both *S. aureus* and methicillin resistant *Staphylococcus aureus* (1.56 and 1.56 μM , respectively). Some compounds in combination with antibiotics exhibited potentiate Gram-positive antibacterial activity; compound **2e** was found to display unaided or synergistic efficacy against MRSA. In particular, when compound **2e** is combined with ofloxacin, it has a good synergistic effect against MRSA. Moreover, electron microscopy revealed that compound **2e** inhibits biofilm formation and effectively eradicates preformed biofilm. MTT assay showed that compound **2e** displays as low toxicity as CCCP. Overall, our data showed that the aromatic hydrazone is a promising scaffold for anti-staphylococcal drug development.

Received 7th April 2020
Accepted 29th April 2020

DOI: 10.1039/d0ra03124k

rsc.li/rsc-advances

1. Introduction

Antimicrobial resistance (AMR) is an increasingly serious threat to global public health that requires a collaborative global approach across sectors. AMR largely reduces the antibiotic efficacies and increases health care costs, and the situation is getting worse due to the emergence of multidrug-resistant (MDR) bacterial pathogens, such as extended spectrum beta-lactamase *Enterobacteriaceae*, methicillin resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE).^{1,2} Therefore, there is now an urgent need to develop new antibacterial agents with novel targets and new approaches, which could be addressed by developing new antibacterial agents with unique chemical scaffolds.^{3–5}

Mitochondria are well-known for their role as biosynthetic and bioenergetic organelles, which play a critical role in the innate immune response against viral and bacterial infections.^{6,7} As a chemical inhibitor of oxidative phosphorylation in the mitochondria, carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) affects mitochondrial protein synthesis, causes an

uncoupling of the proton gradient, acts essentially as an ionophore and reduces the ability of ATP synthase to function optimally. CCCP causes the gradual destruction of living cells and death of the organism by affecting the respiration and respiration-dependent phosphorylation.^{8,9} Antibiotic accumulation in Gram-negative bacteria is one of the major causes of AMR. CCCP was widely used to study cellular accumulation in Gram-negative bacteria for many small molecules^{10–12} due to its ability to collapse the proton motive force.¹³ As AMR spreads, a promising approach is to restore the effectiveness of existing drugs *via* co-administration with adjuvants that inhibit the growth of drug-sensitive pathogens.^{4,14,15} CCCP in combination with small molecules showed synergistic effect against most of the MDR pathogenic bacterial strains.^{16–20} CCCP in combination with antibiotics could potentiate antibacterial activity.

Since CCCP acts as a protonophore which disperses the membrane proton motive force by modifying the transmembrane electrochemical potential, it simultaneously causes toxicity to the cell of the host.^{21,22} Moreover, the concentration of synergistic antibacterial effect of CCCP is so high (at least 50 μM) that the effective dose may disrupt mitochondrial function to lead to toxicity.^{23–25} Therefore, in this work, a series of aromatic hydrazones were synthesized and evaluated for their antibacterial activity to try and improve antibacterial potency and reduce toxicity. The preliminary screening showed that aromatic hydrazones exhibited potential Gram-positive antibacterial activities. New compounds alone or in combination with antibiotics exhibited potentiate Gram-positive antibacterial activities.

^aSchool of Medicine, Anhui University of Science and Technology, Huainan 232001, China

^bAnhui Prevention and Treatment Center for Occupational Disease, Anhui No. 2 Provincial People's Hospital, Hefei 230041, China. E-mail: hfzj2552@163.com

^cSchool of Pharmacy, Anhui Medical University, Hefei 230032, China

† Electronic supplementary information (ESI) available: The copies of representative ¹H and ¹³C NMR spectra. See DOI: 10.1039/d0ra03124k





Fig. 1 The general strategy in this work.

Therefore, the aromatic residue is a promising scaffold for further antibacterial modifications. Further, a plausible antibacterial mechanism was proposed and investigated *via* scanning electron microscopy (SEM) and transmission electron microscopy (TEM) (Fig. 1).

2. Results and discussion


2.1. Chemistry

The synthetic route to compounds **2a–2q** is illustrated in Scheme 1. The nitrosation of the aromatic amines (**1**) with nitrous acid (*in situ* from sodium nitrite and concentrated

hydrochloric acid) led to aromatic diazonium salts, which can be used to next reaction without purification. The diazonium salt as the key intermediate underwent a condensation reaction with methylene of malononitrile to yield the title compound **2**.

2.2. Antibacterial activity of compounds **2a–2q**

In order to determine the antimicrobial potential of aromatic hydrazones, they were evaluated in either Mueller–Hinton (MH) broth or Sabouraud Dextrose Agar (SDA) using a micro-broth dilution method against a panel of bacteria and fungi, including two Gram-positive bacteria: *Staphylococcus aureus* ATCC 25923 (SA) and Methicillin Resistant *Staphylococcus*



Scheme 1 Synthesis of aromatic hydrazones **2a–2q**. Reaction conditions and reagents: (i) HCl , NaNO_2 , 0°C , 1 h; (ii) $\text{CH}_2(\text{CN})_2$, CH_3COONa , 0°C , 2 h.

Table 1 MIC (μM)^a of aromatic hydrazones against Gram-positive bacteria

Compounds ^b	SA	MRSA
2a	3.12	6.25
2b	>200	>200
2c	50	100
2d	100	100
2e	1.56	1.56
2f	25	50
2g	100	100
2h	6.25	12.50
2i	50	100
2j	1.56	1.56
2k	>200	>200
2l	200	>200
2m	200	>200
2n	25	100
2o	100	100
2p	50	100
2q	100	50
A	25	100
B	0.63	1.25
C	7.50	7.50

^a MICs representing mean values of at least three replicates. ^b A: cefoxitin, B: ofloxacin, C: linezolid.

aureus (MRSA); two Gram-negative bacteria: *Pseudomonas aeruginosa* ATCC 9027 (PA) and *Escherichia coli* ATCC 8739 (EC); and *Candida albicans* ATCC 10231 (CA), respectively. The results showed that compounds 2a–2q showed no anti-microbial activity against Gram-negative bacteria and fungi (MICs > 200 μM , except for 2a, MIC = 50 μM for fungi), while some of

compounds exhibited the moderate to high level of antibacterial activity against Gram-positive bacteria (Table 1). Amongst them, compounds 2e and 2j showed better activity than CCCP (2a) against both *S. aureus* and MRSA (MICs = 1.56 μM), which are even better than cefoxitin and linezolid, and similar with the MICs of ofloxacin. The growth inhibition effects of compounds 2a, 2e and 2j were further investigated against both *S. aureus* and MRSA. The results confirmed that both compounds 2e and 2j were able to inhibit the growth of *S. aureus* and MRSA effectively at the MIC or higher concentrations. Once the concentration drops down to half or less of the MICs, they could only slow down the growing rate of *S. aureus* and MRSA during logarithmic period, while the growth could be recovered after being incubated for longer time (Fig. 2).

2.3. SAR analysis

The structure–activity relationship (SAR) analysis are as followed: (i) when the aromatic ring of carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) was substituted by heterocycle, the antibacterial activity against Gram-positive bacteria was significantly decreased (such as 2b, 2c and 2k); (ii) the phenyl ring with strong electron-withdrawing substituent ($-\text{NO}_2$ and $-\text{CF}_3$) showed the moderate antibacterial activity (such as 2d–2h, 2j and 2p); (iii) further, *para*-substituted group ($-\text{NO}_2$ and $-\text{CF}_3$) exhibited better activity than *meta*-substituted group, e.g. for *S. aureus* and MRSA (MIC values), 2e (1.56, 1.56 μM), 2h (6.25, 12.5 μM) > 2f (25, 100 μM), 2g (100, 100 μM); 2j (1.56, 1.56 μM) > 2d (100, 100 μM), 2p (50, 100 μM).

2.4. Cytotoxicity assays

The human hepatic L02 cells were treated with different concentrations of tested compound (3.125, 6.25, 12.5, 25, 50




Fig. 2 *S. aureus* and MRSA growth inhibition curves. Titration curves showing the effect of different concentrations of compounds 2e and 2j on the growth of *S. aureus* (A and B) and MRSA (C and D). Each OD point presented is the average values of three tests and all experiments are internally controlled. Data are presented as the mean \pm standard deviation ($n = 3$).






Fig. 3 Cell viability assay of tested compounds to L02 cells. Data are presented as the mean \pm standard error ($n = 3$), one-way ANOVA (vs. control), * $P < 0.05$, ** $P < 0.01$.

and 100 μM), and cell viability was measured after 24 h using MTT method. As shown in Fig. 3, compounds **2a**, **2e** and **2j** at the test concentrations (3.125–50 μM) had no obvious cytotoxicity against L02 cells, and the relative cell viabilities of treated cells were all more than 70%.

2.5. Checkerboard assay

To develop a feasible medical application, active compounds **2a**, **2e** and **2j** were tested in combination with clinical antibiotics on SA and MRSA by checkerboard assay in order to evaluate their ability to improve the anti-bacterial activity.²⁰ Each checkerboard test generates many different combinations and, by convention, the FIC value of the most effective combination was used in calculating the fractional inhibitory concentration index (FICI). FICI was calculated by adding both FICs:

Table 2 Synergistic activity assays on MRSA

Compounds		MIC alone (μM)		MIC combination (μM)		FICI	Mode of action
A	B	A	B	A	B		
2a + ofloxacin		6.25	1.25	3.12	0.04	0.53	Additive
2e + ofloxacin		1.56	1.25	0.39	0.04	0.28	Synergy
2j + ofloxacin		1.56	1.25	0.78	0.04	0.53	Additive
2a + cefoxitin		6.25	50.00	3.12	1.56	0.53	Additive
2e + cefoxitin		1.56	50.00	0.78	1.56	0.53	Additive
2j + cefoxitin		1.56	50.00	0.78	1.56	0.53	Additive
2a + linezolid		6.25	7.50	3.12	0.47	0.56	Additive
2e + linezolid		1.56	7.50	0.78	0.47	0.56	Additive
2j + linezolid		1.56	7.50	0.78	1.90	0.75	Additive




Fig. 4 Electronic microscopies of MRSA (A–C). Scanning electronic microscopic images of MRSA and (D–F) Transmission electronic microscopic images of MRSA. (A and D) represent untreated bacteria. (B and E) represent bacteria treated with compound **2e** at 1/2 MIC. (C and F) represent bacteria treated with compound **2e** at 1/2 MIC and ofloxacin of 1/8 MIC.



$$FICI = FIC_A + FIC_B = C_A^{comb}/MIC_A^{alone} + C_B^{comb}/MIC_B^{alone}$$

where MIC_A^{alone} and MIC_B^{alone} are the MICs of compound **A** and **B** when acting alone and C_A^{comb} and C_B^{comb} are concentrations of compounds **A** and **B** at the isoeffective combinations. The FICI was interpreted as synergistic when it was ≤ 0.5 , additional effects when $0.5 < FICI \leq 1.0$, indifferent when $1.0 < FICI \leq 2.0$, and antagonistic when $FICI > 2.0$, and any value between was interpreted as indifferent.

As shown in Table 2, when compound **2a** was used in combination with antibiotics, MIC was reduced 2-fold, but for compound **2e**, MIC was reduced 4-fold. Moreover, compounds **2a**, **2e** and **2j** could significantly improve the performance of clinical antibiotics, for example, ofloxacin, cefoxitin and linezolid lowered their MIC values from 1.25, 50.0 and 7.5 μ M to 0.04, 1.56 and 0.47 μ M, respectively. Calculations of FIC and FICI (always less than 1.0) obtained by checkerboard assays on SA and MRSA showed at least additive effects of active compounds (**2a**, **2e** and **2j**) with clinical antibiotics. When compound **2e** was combined with ofloxacin, FICI value of 0.28 suggested a synergistic effect. Therefore, worthy of note is the prophylactic purpose that low doses of clinical antibiotics plus a protonophore may be developed as an anti-MRSA therapy by inhibiting biofilm.

2.6. Electron microscope

To elucidate the effects of compound **2e** on MRSA, both the Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) were used to observe the bacteria after being treated with either compound **2e** alone or in combination with ofloxacin. As shown in Fig. 4, SEM results revealed that untreated MRSA form biofilms in normal growth condition, while the biofilms were eradicated when treated with compound **2e** at 1/2 MIC concentration or in its combination with 1/8 MIC of ofloxacin. Furthermore, TEM results revealed that the regular cell conformation was destructed and the leakage of cellular substances under the treatment of compound **2e** in combination with ofloxacin.

3. Conclusion

In summary, a series of aromatic hydrazones were synthesized and evaluated for their antibacterial activities. Some compounds showed potential antimicrobial activity against Gram-positive bacteria, amongst them, compounds **2e** and **2j** had the lowest MICs against both *S. aureus* and MRSA (1.56 μ M), and the growth inhibition assay confirmed the inhibition effects. SAR showed that (i) for aromatic hydrazones containing heterocycles, the antibacterial activity against Gram-positive bacteria was significantly decreased (**2a** > **2b**, **2c**, **2k**); (ii) the phenyl ring with strong electron-withdrawing substituent ($-\text{NO}_2$ and $-\text{CF}_3$) showed the moderate antibacterial activity (**2d–2h**, **2j** and **2p**); (iii) further, *para*-substituted group ($-\text{NO}_2$ and $-\text{CF}_3$) exhibited better activity than *meta*-substituted group, e.g. for *S. aureus* and MRSA (MIC values), **2e**, **2h** > **2f**, **2g**; **2j** > **2d**, **2p**. Aromatic hydrazones in combination with clinical antibiotics

exhibited better Gram-positive antibacterial activities, especially when compound **2e** was used in combination with ofloxacin, in which the synergistic effect was observed. MTT assay showed that the toxicity of compound **2e** was low as that of CCCP. Further, electron microscopy showed that compound **2e** possesses the capability to inhibit the formation of biofilm and eradicate already existing biofilm. In sum, compound **2e** displayed antibacterial activity against MRSA through inhibiting biofilm, especially improved the bactericidal effects of clinical antibiotics by synergistic effect. Therefore, the aromatic residue is a promising scaffold for further antibacterial modifications.

4. Materials and methods

4.1. Chemistry

All reagents were purchased from commercial sources and were used without further purification. Melting points (uncorrected) were determined on a XT4MP apparatus (Taikang Corp., Beijing, China). ^1H NMR and ^{13}C NMR spectra were recorded on Bruker AV-600 or AV-400 MHz instruments in CDCl_3 . Chemical shifts are reported in parts per million (δ) downfield from the signal of tetramethylsilane (TMS) as internal standards. Coupling constants are reported in Hz. The multiplicity is defined by s (singlet), d (doublet), t (triplet), or m (multiplet). High resolution mass spectra (HRMS) were obtained on an Agilent 1260-6221 TOF mass spectrometry. Column and thin-layer chromatography (CC and TLC, resp.) were performed on silica gel (200–300 mesh) and silica gel GF₂₅₄ (Qingdao Marine Chemical Factory) respectively.

4.2. General procedures for synthesis of 2-(2-arylhydrazono) malononitriles **2a–2q**

To a solution of the aromatic amine (15 mmol) and concentrated HCl (37%, 13.8 mL) in H_2O (75 mL) was dropwise added NaNO_2 (15 mmol, 1.04 g) in H_2O (50 mL) for 1 h in an ice bath, and the mixture was stirred for 30 min. Then, the reaction solution was added to a solution of $\text{CH}_2(\text{CN})_2$ (20 mmol, 1.26 mL) and NaOAc (31 mmol, 38.1 g) in H_2O (130 mL) under continuous stirring at 0 $^\circ\text{C}$. After 2 hours, the reaction mixture was filtrated, washed twice with water, and the residue was recrystallized from ethanol to give the title compounds **2a–2q**.

N-(3-Chlorophenyl)carbonohydrazonoyl dicyanide (2a). Yellow-green powder, yield, 80%; mp 131–133 $^\circ\text{C}$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.49–7.40 (m, 3H), 7.26 (d, $J = 6.9$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 142.71, 135.01, 130.30, 125.54, 116.69, 114.73, 113.44, 109.53, 85.54.

N-(2-Chloropyridin-4-yl)carbonohydrazonoyl dicyanide (2b). Yellow powder, yield, 83%; mp 92–94 $^\circ\text{C}$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.25 (d, $J = 5.3$ Hz, 1H), 7.29 (d, $J = 5.1$ Hz, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 153.60, 151.86, 149.81, 114.60, 111.33, 110.86, 110.60, 86.25. TOF-HRMS: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_8\text{H}_4\text{ClN}_5$; 206.0155; found: 206.0156.

N-(2-Methoxypyridin-4-yl)carbonohydrazonoyl dicyanide (2c). Orange powder, yield, 78%; mp 42–43 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.17 (d, $J = 5.8$ Hz, 1H), 6.90 (dd, $J = 5.7, 1.7$ Hz, 1H), 6.67 (s, 1H), 3.97 (s, 3H). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$)



δ 163.06, 115.16, 110.59, 106.22 (2C), 95.33 (2C), 87.73, 54.98. TOF-HRMS: m/z $[M + H]^+$ calcd for $C_9H_7N_5O$: 202.0651; found: 202.0649.

***N*-(4-Fluoro-3-(trifluoromethyl)phenyl)carbonohydrazonoyl dicyanide (2d).** Earthy red powder, yield, 78%; mp 30 °C; 1H NMR (400 MHz, $CDCl_3$) δ 10.06 (s, 1H), 7.82–7.42 (m, 2H), 7.31 (t, J = 9.1 Hz, 1H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 157.75, 138.80, 122.89, 122.78, 119.27, 117.72, 115.36, 114.46, 110.15, 86.63.

***N*-(4-Nitrophenyl)carbonohydrazonoyl dicyanide (2e).** Bright yellow powder, yield, 81%; mp 40–41 °C; 1H NMR (400 MHz, DMSO- d_6) δ 8.19 (d, J = 9.1 Hz, 2H), 7.49 (d, J = 9.1 Hz, 2H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 142.71, 125.19 (2C), 118.14 (2C), 117.98, 113.20, 94.76, 82.41. TOF-HRMS: m/z $[M + H]^+$ calcd for $C_9H_6N_5O_2$: 230.0547; found: 230.0550.

***N*-(3-Nitrophenyl)carbonohydrazonoyl dicyanide (2f).** Yellow powder, yield, 82%; mp 144–145 °C; 1H NMR (400 MHz, DMSO- d_6) δ 8.21 (t, J = 2.1 Hz, 1H), 8.08–7.96 (m, 1H), 7.91–7.77 (m, 1H), 7.68 (t, J = 8.2 Hz, 1H). ^{13}C NMR (151 MHz, DMSO- d_6) δ 148.91, 144.78, 131.33, 123.26, 119.80, 115.30, 111.59, 110.85, 85.83.

***N*-(4-Chloro-3-nitrophenyl)carbonohydrazonoyl dicyanide (2g).** Yellow powder, yield, 80%; mp 40–41 °C; 1H NMR (400 MHz, DMSO- d_6) δ 7.73 (s, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.48 (d, J = 8.7 Hz, 1H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 158.90, 153.42, 136.88, 129.41, 126.08, 122.79, 121.01, 119.43, 81.46.

***N*-(2-Methyl-4-nitrophenyl)carbonohydrazonoyl dicyanide (2h).** Dark green powder, yield, 85%; mp 41 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.57 (s, 1H), 8.18 (dt, J = 27.6, 12.5 Hz, 2H), 7.70 (d, J = 8.9 Hz, 1H), 2.51 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 146.56, 144.00, 129.46, 126.58, 122.61, 118.70, 114.81, 110.23, 87.24, 17.47.

***N*-(2,3-Dihydrobenzo[*b*][1,4]dioxin-6-yl)carbonohydrazonoyl dicyanide (2i).** Earth orange powder, yield, 84%; mp 90 °C; 1H NMR (400 MHz, DMSO- d_6) δ 6.99–6.94 (m, 1H), 6.92–6.87 (m, 1H), 4.25 (s, 4H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 144.21, 142.25, 136.12, 118.20, 115.24, 110.81, 110.17, 105.94, 83.35, 64.68, 64.49.

***N*-(2-Fluoro-5-(trifluoromethyl)phenyl)carbonohydrazonoyl dicyanide (2j).** Orange powder, yield, 90%; mp 33–35 °C; 1H NMR (400 MHz, DMSO- d_6) δ 7.80 (d, J = 6.9 Hz, 1H), 7.68–7.51 (m, 2H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 155.03, 132.74, 126.42, 124.09, 124.06, 118.49, 117.50, 115.37, 110.80, 87.05. TOF-HRMS: m/z $[M + Na]^+$ calcd for $C_{10}H_4F_4N_4Na$: 279.0264; found: 279.0261.

***N*-(5-Phenyl-1H-pyrazol-3-yl)carbonohydrazonoyl dicyanide (2k).** Yellow powder, yield, 89%; mp 138–139 °C; 1H NMR (400 MHz, DMSO- d_6) δ 9.33 (s, 2H), 8.17 (d, J = 7.5 Hz, 2H), 7.66 (s, 1H), 7.53 (dt, J = 13.8, 7.1 Hz, 3H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 156.98, 150.06, 143.24, 131.62, 130.41, 129.41 (2C), 127.14 (2C), 116.37, 105.62, 96.13. TOF-HRMS: m/z $[M + H]^+$ calcd for $C_{12}H_8N_6$: 237.0801; found: 237.0805.

***N*-(4-Acetamidophenyl)carbonohydrazonoyl dicyanide (2l).** Yellow powder, yield, 70%; mp 45–46 °C; 1H NMR (400 MHz, DMSO- d_6) δ 10.07 (s, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.40 (d, J = 8.8 Hz, 2H), 2.05 (s, 3H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 168.77,

137.82, 137.56, 120.18 (2C), 117.56 (2C), 115.42, 110.94, 83.40, 24.43.

***N*-(4-Carbamoylphenyl)carbonohydrazonoyl dicyanide (2m).** Dark yellow green powder, yield, 82%; mp 155–157 °C; 1H NMR (400 MHz, DMSO- d_6) δ 7.96 (s, 1H), 7.90 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 7.33 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 167.69, 146.72, 131.09 (2C), 129.38 (2C), 116.90, 116.29, 111.71, 84.09.

***N*-(4-Acetylphenyl)carbonohydrazonoyl dicyanide (2n).** Bright yellow powder, yield, 91%; mp 254–255 °C; 1H NMR (400 MHz, DMSO- d_6) δ 7.93 (d, J = 8.6 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 2.51 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 197.03, 150.90, 133.24, 130.23 (2C), 117.73 (2C), 113.00, 99.98, 82.71, 26.99.

***N*-(4-Cyanophenyl)carbonohydrazonoyl dicyanide (2o).** Yellow-green powder, yield, 88%; mp 116–117 °C; 1H NMR (400 MHz, DMSO- d_6) δ 7.78 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 149.82, 134.03 (2C), 119.57, 118.29 (2C), 116.88, 112.26, 106.62, 84.34.

***N*-(3,5-Bis(trifluoromethyl)phenyl)carbonohydrazonoyl dicyanide (2p).** Light yellow powder, yield, 70%; mp 113–115 °C; 1H NMR (400 MHz, $CDCl_3$) δ 7.86 (s, 2H), 7.73 (s, 1H).

***N*-(5-Acetyl-4-hydroxy-2-methoxyphenyl)carbonohydrazonoyl dicyanide (2q).** Dark green powder, yield, 70%; mp 132–134 °C; 1H NMR (400 MHz, DMSO- d_6) δ 12.58 (s, 1H), 7.79 (s, 1H), 6.69 (s, 1H), 3.95 (s, 3H), 2.59 (s, 3H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 203.23, 162.86, 156.87, 123.39, 122.67, 114.81, 113.71, 110.20, 100.94, 85.12, 57.21, 27.67.

4.3. Culture conditions and treatments

L02 (normal human liver) cell lines were purchased from the Russian Cell Culture Collection (Institute of Cytology Russian Academy of Science, Saint Petersburg, Russia). L02 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, USA) supplemented with 2 mM L-glutamine (Sigma-Aldrich, UK), 10% fetal bovine serum (Invitrogen, USA), 50 μ g mL $^{-1}$ gentamicin sulfate (Invitrogen, USA) at 37 °C and 5% CO $_2$. All compounds were dissolved in 100% DMSO (Sigma-Aldrich, UK) to 100 mM stock solutions and diluted in completed DMEM immediately before addition to the assay plates. DMSO was maintained at a final concentration of 0.1%.

4.4. Minimum inhibitory concentrations (MICs)

The MICs of tested compounds were determined using Muelser–Hinton (MH) broth micro-broth dilution assay established by the Clinical Laboratory Standards Institute (CLSI) in 96-well micro-test plates. The final test concentration ranged from 0.39 to 200 μ M and the bacterial inocula was 10 8 CFU mL $^{-1}$. After 18–20 hours of incubation at 37 °C, the MICs were determined to be the lowest concentration of tested compound that inhibited the apparent increase in microorganisms. Each experiment was repeated at least 3 times to report the MIC value.²⁶

4.5. Inhibition of bacterial growth

The effect of concentrations ranging from 0.5 to 4 times MIC of the active compounds on the growth of *S. aureus* or MRSA was



quantified after incubation at 35 °C for 0, 4, 8, 10, 18, 22 and 26 hours. At each time point, an aliquot (100 µL) was pipetted and measured for the A_{450} nm. The experiment was performed in three biologically independent assays, each tested in triplicate.

4.6. Checkerboard assays

The synergistic effect of the combination of clinical antibacterials with the tested compounds was determined by checkerboard microdilution assays. In brief, checkerboards were set up with double dilutions of compounds **2a** (0–12.5 µM) or **2e** (0–3.12 µM) or **2j** (0–3.12 µM) in the horizontal wells and ofloxacin (0–2.5 µM) or cefoxitin (0–100 µM) or linezolid (0–14 µM) in the vertical wells. Then 50 µL each was arranged on the rows and columns of the plate, and 100 µL of MRSA was added to the wells and bacteria inocula of 5×10^8 CFU mL⁻¹. After incubation at 35 °C for 20 hours in 96-well micro-test plates. Aromatic hydrazones were further tested to determine their nature of interaction (synergy, antagonism, additive or no interaction) with ofloxacin, cefoxitin and linezolid and expressed as the fractional inhibitory concentration index (FICI) for each agent.

4.7. Cell viability

Cell viability was performed against L02 (normal human liver cell line) cells using the MTT assay. L02 cells were grown in DMEM containing 10% fetal calf serum, 100 units per mL penicillin and 100 µg mL⁻¹ streptomycin at 37 °C in a 5% CO₂ incubator. L02 cells were seeded at 1×10^4 cells per well in 96-well micro-test plates. After 24 h of culture, the cells were treated with different concentrations of tested compound. After 24 h, 20 µL of 0.5 mg mL⁻¹ MTT reagent was added to the cells and incubated for 4 h. After 4 h, the liquid in the well was discarded, and then 150 µL of DMSO was added to dissolve the formazan. The absorbance value (OD₅₇₀) was measured at 570 nm. The cell percentage survival rate was calculated by setting the density of formazan formed in the blank group to 100% viability as a control. Cell viability (%) = compound (OD₅₇₀)/blank (OD₅₇₀) × 100%. Each compound was tested in triplicate.

4.8. Electron microscope

MRSA (ATCC 43300) was grown overnight at 37 °C on Mueller–Hinton Agar. The bacteria were harvested and the OD of bacteria suspended in MHB was adjusted to ~0.5 MacFarlane units so as to give 5×10^7 CFU mL⁻¹. Bacteria were then aliquoted into 10 mL tubes and compound **2e** dissolved in DMSO was added to give a final concentration ranging from 0.5 to 4 mg L⁻¹ (two fold serial dilutions). After incubation at 37 °C for 24 h, the bacteria were harvested by centrifugation at 4000 rpm, and cell pellets were then re-suspended with 10 mM PBS, pH 7.2 and harvested at 4000 rpm. The bacteria were fixed using 2.5% glutaraldehyde for 3 h, following by washing with 0.1 M PBS (pH 7.2) for three times. The washing buffer was then removed and the bacteria were post-fixed in 1% OsO₄ for 2 h. The OsO₄ were then pipetted out into an osmium waste bottle and the bacteria were washed in PBS (pH 7.2) for three times. Fixed microbial pellets were processed in graded alcohols, propylene oxide, and araldite and cured for 48 h at 60 °C. Sample were finally stained

with uranyl acetate and lead citrate before examine with Hitachi TEM system at an accelerating voltage of 80 kV. The SEM model used is the Hitachi su8100 at 3.0 kV voltage.²⁷

4.9. Statistical analysis

All results were expressed as mean values ± standard deviation. One-way analysis of variance followed by Dunnett's post hoc test was used for all comparisons.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

Financial support was provided by the Natural Science Foundation of Anhui provincial Department of Education (KJ2019ZD21, KJ2018B12), and Provincial Natural Science Foundation of Anhui (2008085MH261).

References

- 1 K. M. G. O'Connell, J. T. Hodgkinson, H. F. Sore, M. Welch, G. P. C. Salmond and D. R. Spring, *Angew. Chem., Int. Ed.*, 2013, **52**(41), 10706–10733.
- 2 R. Tommasi, D. G. Brown, G. K. Walkup, J. I. Manchester and A. A. Miller, *Nat. Rev. Drug Discovery*, 2015, **14**, 529–542.
- 3 G. D. Wright, *Nat. Prod. Rep.*, 2017, **34**(7), 694–701.
- 4 M. Tyers and G. D. Wright, *Nat. Rev. Microbiol.*, 2019, **17**, 141–155.
- 5 V. Cattoir and B. Felden, *J. Infect. Dis.*, 2019, **220**(3), 350–360.
- 6 S. E. Weinberg, L. A. Sena and N. S. Chandel, *Immunity*, 2015, **42**, 406–417.
- 7 M. F. Richter, B. S. Drown, A. P. Riley, A. Garcia, T. Shirai, R. L. Svec and P. J. Hergenrother, *Nature*, 2017, **545**(7654), 299–304.
- 8 B. Z. Cavari and Y. Avi-Dor, *Biochem. J.*, 1967, **103**(2), 601–608.
- 9 P. Mishra and D. C. Chan, *J. Cell Biol.*, 2016, **212**, 379–387.
- 10 O. Lomovskaya, M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida and V. J. Lee, *Antimicrob. Agents Chemother.*, 2001, **45**, 105–116.
- 11 T. D. Davis, C. J. Gerry and D. S. Tan, *ACS Chem. Biol.*, 2014, **9**, 2535–2544.
- 12 H. Cai, K. Rose, L.-H. Liang, S. Dunham and C. Stover, *Anal. Biochem.*, 2009, **385**, 321–325.
- 13 M. Ghoul, M. Pommepuy, A. Moillo-Batt and M. Cormier, *Appl. Environ. Microbiol.*, 1989, **55**, 1040–1043.
- 14 J. B. Michel, P. J. Yeh, R. Chait, R. C. Moellering Jr and R. Kishony, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**(39), 14918–14923.
- 15 R. C. Allen and S. P. Brown, *mBio*, 2019, **10**(5), e01831-19.
- 16 N. Tharmalingam, E. Jayamani, R. Rajamuthiah, D. Castillo, B. B. Fuchs, M. J. Kelso and E. Mylonakis, *Future Med. Chem.*, 2017, **9**(12), 1401–1411.



- 17 J. M. Stokes, C. R. Macnair, B. Ilyas, S. French, J.-P. Côté, C. Bouwman, M. A. Farha, A. O. Sieron, C. Whitfield, B. K. Coombes and E. D. Brown, *Nat. Microbiol.*, 2017, **2**, 17028.
- 18 D. Sinha, S. Pandey, R. Singh, V. Tiwari, K. Sad and V. Tandon, *Sci. Rep.*, 2017, **7**, 44419.
- 19 C. Chen and K. Yang, *Bioorg. Chem.*, 2019, **93**, 103286.
- 20 S. Sabatini, M. Piccioni, T. Felicetti, S. De Marco, G. Manfroni, R. Pagiotti, M. Nocchetti, V. Cecchetti and D. Pietrella, *RSC Adv.*, 2017, **7**, 37007–37014.
- 21 J. W. Park, S. Y. Lee, J. Y. Yang, H. W. Rho, B. H. Park, S. N. Lim, J. S. Kim and H. R. Kim, *Biochim. Biophys. Acta*, 1997, **1344**, 132–138.
- 22 A. Mahamoud, J. Chevalier, S. Alibert-Franco, W. V. Kern and J. M. Pagès, *J. Antimicrob. Chemother.*, 2007, **59**, 1223–1229.
- 23 K. Kansaku, S. Takeo, N. Itami, A. Kin, K. Shirasuna, T. Kuwayama and H. Iwata, *PLoS One*, 2017, **12**(11), e0188099.
- 24 X. Zhang, Y. Zhang, F. Wang, C. Wang, L. Chen, H. Liu, H. Lu, H. Wen and T. Zhou, *Int. J. Antimicrob. Agents*, 2018, **52**(2), 226–232.
- 25 J. Fedorowicz, J. Sączewski, A. Konopacka, K. Waleron, D. Lejnowski, K. Ciura, T. Tomašič, Ž. Skok, K. Savijoki, M. Morawska, S. Gilbert-Girard and A. Fallarero, *Eur. J. Med. Chem.*, 2019, **179**, 576–590.
- 26 I. Wiegand, K. Hilpert and R. E. Hancock, *Nat. Protoc.*, 2008, **3**(2), 163–175.
- 27 K. Xu, S. He, S. Chen, G. Qiu, J. Shi, X. Liu, X. Wu, J. Zhang and W. Tang, *Eur. J. Med. Chem.*, 2018, **154**, 144–154.

